New study tracks Long-Term safety of NF1 drug in kids

NCT ID NCT05388370

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study monitors the safety of selumetinib in children aged 3 to 18 with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas. Researchers will track potential side effects on the heart, bones, muscles, liver, eyes, and puberty. The goal is to better understand the drug's risks in real-world use across Europe and Israel.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PLEXIFORM NEUROFIBROMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neurofibromatosis type 1 plexiform neurofibroma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Research Site

    Vienna, Austria

  • Research Site

    Amiens, France

  • Research Site

    Angers, France

  • Research Site

    Bordeaux, France

  • Research Site

    Lille, France

  • Research Site

    Lyon, France

  • Research Site

    Marseille, France

  • Research Site

    Paris, France

  • Research Site

    Rennes, France

  • Research Site

    Strasbourg, France

  • Research Site

    Toulouse, France

  • Research Site

    Tours, France

  • Research Site

    Vandœuvre-lès-Nancy, France

  • Research Site

    Villejuif, France

  • Research Site

    Dresden, Germany

  • Research Site

    Duisburg, Germany

  • Research Site

    Hamburg, Germany

  • Research Site

    Hanover, Germany

  • Research Site

    München, Germany

  • Research Site

    Tübingen, Germany

  • Research Site

    Petah Tikva, Israel

  • Research Site

    Ramat Gan, Israel

  • Research Site

    Tel Aviv, Israel

  • Research Site

    Florence, Italy

  • Research Site

    Genova, Italy

  • Research Site

    Milan, Italy

  • Research Site

    Padova, Italy

  • Research Site

    Pavia, Italy

  • Research Site

    Roma, Italy

  • Research Site

    Torino, Italy

  • Research Site

    Trieste, Italy

  • Research Site

    Rotterdam, Netherlands

  • Research Site

    Lisbon, Portugal

  • Research Site

    Porto, Portugal

  • Research Site

    Barcelona, Spain

  • Research Site

    Madrid, Spain

  • Research Site

    Málaga, Spain

  • Research Site

    Santiago de Compostela, Spain

  • Research Site

    Seville, Spain

  • Research Site

    Basel, Switzerland

  • Research Site

    Bern, Switzerland

  • Research Site

    Lausanne, Switzerland

  • Research Site

    Sankt Gallen, Switzerland

  • Research Site

    London, United Kingdom

  • Research Site

    Manchester, United Kingdom

  • Research Site

    Newcastle upon Tyne, United Kingdom